Internal Innovation or Strategic Sourcing? | Ep. 1043
Rethinking Pharma's Growth Engine
Hello Avatar! Welcome back for another week of biotech analysis. Today is Sunday, which means this is our Building Biotech newsletter that is focused on discussing biopharma strategy topics. Today we will dig into how pharma companies are building their pipelines, and why the old model of relying purely on internal R&D is no longer enough. Using fresh 4Q24 data, we’ll explore how internal innovation, in-licensing, and acquisitions each contribute to product sales, and what that tells us about where real value is being created. Along the way, we'll break down why obesity blockbusters are skewing internal R&D success, why smart licensing is outperforming acquisitions, and how a hybrid model of selective building and buying is becoming the new industry standard. If you want to understand how pharma is really fueling its next wave of growth, you’re in the right place.
We are now publishing 7x per week according to the following cadence:
Mondays: Stocks
Tuesdays: Biotech
Wednesdays: Podcast
Thursdays: Markets
Fridays: News
Saturdays: Podcast
Sundays: Strategy
We are also publishing unique content on X - be sure to follow up if you are not already @BowTiedBiotech. And to check-out the archive of our work on X you can find it on our website at: BowtiedBiotech.subtack.com/x-articles.
SUBSCRIBE TO PODCAST HERE:
Please help spread the work by subscribing and hitting the share button if you are enjoying our bi-weekly newsletters!
Enough shilling for the day, lots to cover this week, let's get started!
Introduction: The Hidden Costs Behind Pharma’s Brightest Products
The pharmaceutical industry often paints a simple picture: breakthrough cures come from heroic internal research. But when we peel back the layers, the reality is much more complicated. A large share of blockbuster drugs fueling today's pharma giants were not invented in-house. Instead, they were in-licensed or acquired. As pressures on productivity rise, understanding when internal R&D actually pays off, and when external sourcing offers better returns is critical for anyone navigating the future of biotech and pharma.
Recent data from 4Q24 paints a stark portrait: while internally developed drugs generated $14 billion in sales among products approved since 2020, a closer look reveals that four obesity drugs accounted for nearly two-thirds of that total. Strip those out, and internal R&D looks far less impressive. Meanwhile, in-licensed products posted even stronger average sales numbers, while acquired products significantly underperformed expectations. It begs the question: is pharma investing in the right strategy?
